Results 51 to 60 of about 1,097,021 (302)

Immune Checkpoint Inhibitors and Neurotoxicity

open access: yesCurrent Neuropharmacology, 2021
: Immune checkpoint inhibitors (ICIs) have recently been used as a promising treatment for cancer, while their toxicity and immune-related side effects can be seen in any organ, including the nervous system. In contrast to other immune-related adverse events (irAEs), neurological irAEs (nAEs) are rare, with ...
Zhao, Zhiyi   +4 more
openaire   +3 more sources

Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives

open access: yesFrontiers in Pharmacology, 2023
In recent years, cancer immunotherapy has made remarkable achievements. Immune checkpoint inhibitors (ICIs) have been used successfully in several types of cancer in the past decade.
Zherui Liu   +6 more
doaj   +1 more source

Treatment patterns of melanoma by BRAF mutation status in the USA from 2011 to 2017: a retrospective cohort study

open access: yesMelanoma Management, 2019
Aim: To describe treatment changes from 2011 to 2017 and demographic/clinical characteristics of patients with advanced melanoma who received systemic therapy by BRAF status.
Shweta Shah   +4 more
doaj   +1 more source

The Future of Checkpoint Inhibitors in Uveal Melanoma: A Narrative Review

open access: yesOphthalmology and Therapy
Introduction Immune checkpoint inhibitors have made tremendous progress over the last decade in the treatment of cutaneous melanoma, but their application in uveal melanoma treatment is less successful, owing in part to the immunological privilege of the
Jinyu Wang, Zehua Li, Hongbo Yin
doaj   +1 more source

Immune checkpoint inhibitors in therapy of non-small cell lung cancer (a review)

open access: yesZaporožskij Medicinskij Žurnal, 2021
Aim. Based on scientific literature data, to evaluate the effectiveness of the use of immune checkpoint inhibitors (ICI) in the treatment of non-small cell lung cancer (NSCLC). Materials and methods.
O. P. Kolesnik, V. V. Mykhailychenko
doaj   +1 more source

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

open access: yesFEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang   +2 more
wiley   +1 more source

Update on Immune Checkpoint Inhibitors for Conjunctival Melanoma

open access: yesJournal of Ophthalmic & Vision Research, 2022
The management of conjunctival melanoma is challenging due to the more frequent local recurrence and metastasis compared to other conjunctival neoplasms.
Ho-Seok Sa, Claire Daniel, Bita Esmaeli
doaj   +1 more source

Ligand‐dependent transcriptional heterogeneity in cell cycle gene expression delays G1/S entry

open access: yesFEBS Letters, EarlyView.
EGF and HRG induce distinct G1/S progression programs in ErbB2‐amplified BT474 breast cancer cells. Despite activating the potent ErbB2–ErbB3 heterodimer, HRG does not accelerate cell‐cycle entry. Instead, EGF promotes earlier restriction‐point passage via ERK–FOS signaling, whereas HRG activates the AKT–MYC axis, driving transcriptional heterogeneity ...
Ririn Rahmala Febri   +5 more
wiley   +1 more source

Development of Extragenital Lichen Sclerosus in Malignant Melanoma Patients Treated With Ipilimumab in Combination With Nivolumab

open access: yesFrontiers in Oncology, 2020
The immune checkpoint inhibitors opened a new era for the treatment of melanoma. Nowadays, combined immune checkpoint inhibitors are administered to provide additive or synergistic effects on anti-melanoma immunity.
S. Morteza Seyed Jafari   +2 more
doaj   +1 more source

A context‐dependent modulatory role for eIF6 in acquired resistance to vemurafenib in melanoma

open access: yesFEBS Letters, EarlyView.
Acquired resistance to vemurafenib upregulates the translation factor eIF6 in melanoma cells. Silencing eIF6 in resistant cells reduces proliferation and partially restores drug sensitivity, whereas its overexpression increases sensitivity across melanoma lines regardless of BRAF status, via modulation of mTOR, S6K, and MAPK signaling.
George Kyriakopoulos   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy